A clinical briefing on Viloxazine (Qelbree) availability in 2026 for healthcare providers. Covers supply chain status, prior authorization, pricing, and tools to help patients access this non-stimulant ADHD medication.
If your patients are reporting difficulty filling Viloxazine (Qelbree) prescriptions, you're not alone. While Viloxazine is not on the FDA's drug shortage list, localized availability challenges have persisted into 2026 — driven by brand-only status, cost-related pharmacy stocking decisions, and increased demand for non-stimulant ADHD treatments. This briefing covers what you need to know to manage these challenges in your prescribing practice.
April 2021: FDA approves Viloxazine extended-release capsules (Qelbree) for ADHD in children and adolescents aged 6–17. Supernus Pharmaceuticals launches the product as the first new non-stimulant ADHD medication in over a decade.
March 2022: FDA expands approval to include adults aged 18 and older, significantly broadening the eligible patient population.
2022–2023: Prescribing volumes grow steadily as clinicians adopt Viloxazine as an alternative to stimulants and Atomoxetine. Coincides with the national Adderall shortage, accelerating interest in non-stimulant options.
2024–2025: Ongoing stimulant shortages continue to drive demand for Viloxazine. Patients report increasing difficulty finding Qelbree at chain pharmacies. Supernus maintains manufacturing, but distribution remains uneven due to pharmacy stocking economics.
2026 (current): Viloxazine remains off the FDA shortage list. Availability challenges persist as a localized distribution issue rather than a manufacturing shortfall. No generic alternatives have entered the market.
Supernus Pharmaceuticals continues to manufacture and distribute Viloxazine without reported production constraints. The availability issues your patients experience are primarily at the pharmacy level — not the manufacturing level. The medication exists in the wholesale supply chain, but individual pharmacies may not stock it due to cost or ordering constraints.
Viloxazine coverage varies significantly across payers:
The PA process for Viloxazine typically requires documentation of: ADHD diagnosis, previous treatment trials and their outcomes, and clinical rationale for a non-stimulant option (e.g., substance use history, stimulant intolerance, patient preference, comorbid anxiety).
Insurance coverage is strongest for the FDA-approved indication of ADHD. Off-label use for depression or anxiety — despite Viloxazine's historical use as an antidepressant in Europe — is generally not covered and may trigger claim denials.
The distribution path for Viloxazine follows the standard model: Supernus Pharmaceuticals → national wholesalers (McKesson, Cardinal Health, AmerisourceBergen) → individual pharmacies. At each step, allocation decisions can limit what reaches the pharmacy shelf.
Wholesalers allocate inventory based on a pharmacy's historical purchasing patterns. A pharmacy that hasn't regularly stocked Viloxazine will have a lower allocation — creating a chicken-and-egg problem where low stocking leads to low allocation, which perpetuates low stocking.
Some doses may be more readily available than others. The 200 mg capsule — the most commonly prescribed adult starting dose — tends to have the most consistent availability. The 100 mg and 150 mg capsules, which serve pediatric patients and dose titration, may be less consistently stocked.
Urban areas with multiple pharmacy options generally offer better access. Rural areas and regions with fewer independent pharmacies may face more significant challenges. Patients willing to expand their search radius often find better results.
Qelbree's retail price ranges from $350–$500 per month, depending on dose and pharmacy. This is a significant barrier for patients without adequate insurance coverage.
Supernus offers a Qelbree Savings Card for commercially insured patients, potentially reducing copays to $0 (subject to maximum benefit limits). This program does not apply to patients with government insurance (Medicare, Medicaid, Tricare).
Medicare Part D plans generally cover Viloxazine with prior authorization. Medicaid coverage varies by state. For patients on government insurance who face high out-of-pocket costs, the Supernus Cares Patient Assistance Program may provide free medication to qualifying individuals.
For uninsured or underinsured patients:
Several developments may impact Viloxazine access in the coming years:
Viloxazine occupies an important niche in the ADHD treatment landscape as a non-stimulant, non-controlled option with a novel mechanism of action. The availability challenges your patients face are real but manageable with the right strategies.
As a prescriber, you can make a meaningful difference by:
Share this patient-facing update with patients who are struggling with availability. For a step-by-step practice guide, see our article on how to help your patients find Viloxazine in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
